PVLA files NDA for QTORIN microLM; FDA approval expected in 2027
PVLA advanced its QTORIN platform for rare skin and vascular diseases, filing a lead NDA for microLM and anticipating FDA approval in 2027. The company cites strong IP, regulatory exclusivity and clinical data.